Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice

Blood

Volumn 88, Issue 5, 1996, Pages 1561-1567

  LaCasse, Eric C ^b   Saleh, Mazen T ^b   Patterson, Bruce ^b   Minden, Mark D ^b   Gariépy, Jean ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; FLUORESCEIN ISOTHIOCYANATE; GLOBOTRIAOSYLCERAMIDE; IMMUNOTOXIN; PROTEIN SUBUNIT; VEROTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; BONE MARROW PURGING; CANCER CELL DESTRUCTION; CONTROLLED STUDY; DAUDI CELL; DRUG MECHANISM; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SCID MOUSE; TUMOR XENOGRAFT;

EID: 0029792411     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.5.1561.bloodjournal8851561     Document Type: Article

References (45)

1. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75, 1993
2. Brinkmann U, Pastan I: Immunotoxins against cancer. Biochim Biophys Acta 1198:27, 1994
3. Ghetie V, Vitetta E: Immunotoxins in the therapy of cancers: From bench to clinic. Pharmacol Ther 63:209, 1994
4. Gottstein C, Winkler U, Bohlen H, Diehl U, Engen A: Immunotoxins: Is there a clinical value? Ann Oncol 5:S97, 1994 (suppl)
5. Vallera DA: Immunotoxins: Will their clinical promise be fulfilled? Blood 83:309, 1994
6. O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GT: Shiga toxin: Biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Micro Immunol 180:65, 1992
7. Hofmann SL: Southwestern internal medicine conference: Shiga-like toxins in hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura. Am J Med Sci 306:398, 1993
8. Murray LJ, Habeshaw JA, Wiels J, Greaves MF: Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antobody 38.13) on both normal and malignant germinal-centre B cells. Int J Cancer 36:561, 1985
9. Mangeney M, Richard Y, Coulaud D, Tursz T, Wiels J: CD77: An antigen of germinal center B cells entering apoptosis. Eur J Immunol 21:1131, 1991
10. Schwartz-Albiez R, Dörken B, Möller P, Brodin NT, Monner DA, Kniep B: Neutral glycosphingolipids of the globo-series characterize activation stages corresponding to germinal center B cells. Int Immunol 2:929, 1990
11. k, CD77) produced with a synthetic glycoconjugate as immunogen: Reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors. Int J Cancer 48:848, 1991
12. Kalisiak A, Minniti JG, Oosterwijk E, Old LJ, Scheinberg DA: Neutral glycosphingolipid expression in B-cell neoplasms. Int J Cancer 49:837, 1991
13. Taga S, Mangeney M, Tursz T, Wiels J: Differential regulation of glycosphingolipid biosynthesis in phenotypically distinct Burkitt's lymphoma cell lines. Int J Cancer 61:261, 1995
14. Ghetie M-A, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES: Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites. Cancer Res 51:5876, 1991
15. Vitetta ES: From the basic science of B cells to biological missiles at the bedside. J Immunol 153:1407, 1994
16. Trevisan M, Iscove NN: Phenotypic analysis of murine long-term hemopoietic reconstitutive cells quantitated competively in vivo and comparison with more advanced colony-forming progeny. J Exp Med 181:93, 1995
17. Petric M, Karmali MA, Richardson S, Cheung R: Purification and biological properties of Escherichia coli verocytotoxin. FEMS Microbiol Lett 41:63, 1987
18. Bosma GC, Custer RP, Bosma MJ: A severe combined immunodeficiency mutation in the mouse. Nature 301:527, 1983
19. Fulop GM, Phillips RA: Full reconstitution of the immune deficiency in scid mice with normal stem cells requires low-dose irradiation of the recipients. J Immunol 136:4438, 1986
20. Ramotar K, Boyd B, Tyrell G, Gariépy J, Lingwood C, Brunton J: Characterization of Shiga-like toxin 1 B-subunit purified from overproducing clones of the SLT-1 B cistron. Biochem J 272:805, 1990
21. Mangeney M, Lingwood CA, Taga S, Caillou B, Tursz T, Wiels J: Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res 53:5314, 1993
22. Cohen A, Madrid-Marina V, Estrov Z, Freedman MH, Lingwood CA, Dosch H-M: Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: A mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol 2:1, 1990
23. Mangeney M, Rousselet G, Taga S, Tursz T, Wiels J: The fate of human CD77+ germinal center B lymphocytes after rescue from apoptosis. Molec Immunol 32:333, 1995
24. Ramegowda B, Tesh VL: Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect Immun 64:1173, 1996
25. Farkas-Himsley H, Hill R, Rosen B, Arab S, Lingwood CA: The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc Natl Acad Sci USA 92:6996, 1995
26. Brodin NT, Dahmén J, Nilsson B, Messeter L, Mårtensson S, Heldrup J, Sjögren HO, Lundblad A: Monoclonal antibodies produced by immunization with neoglycoproteins containing Galα1-4Galβ1-4Glcβ-O and Galα1-4Galβ1-4GlcNAcβ-O residues: Useful immunochemical and cytochemical reagents for blood group P antigens and a differentiation marker in Burkitt lymphoma and other B-cell malignancies. Int J Cancer 42:185, 1988
27. +) lymphocytes in scid mice. J Immunol 143:1087, 1989
28. Matsumoto K, Inukai S-i, Isaka T, Aruga N, Nakamura S, Nagasawa T, Naito J: Cell counts in peripheral blood and bone marrow of male C.B-17 scid/scid mice. Lab Animals 29:218, 1995
29. Wiels J, Mangeney M, Tétaud C, Tursz T: Sequential shifts in the three major glycosphingolipid series are associated with B cell differentiation. Int Immunol 3:1289, 1991
30. Gordon J, Mellstedt H, Åman P, Biderfeld P, Björkhplm M, Klein G: Phenotypes in chronic B-lymphocytic leukemia probed by monoclonal antibodies and immunoglobulin secretion studies: Identification of stages of maturation arrest and the relation to clinical findings. Blood 62:910, 1983
31. Murgo AJ, Weinberger BB: Pharmacological bone marrow purging in autologous transplantation: Focus on the cyclophosphamide derivatives. Crit Rev Oncol Hematol 14:41, 1993
32. Gribben JG, Nadler LM: The immunological treatment of human marrow in vitro in transplantation biology. Cancer Treat Res 64:189, 1993
33. Bilgrami S, Silva M, Cardosa A, Miller KB, Ascensao JL: Immunotherapy with autologous bone-marrow transplantation: Rationale and results. Exp Hematol 22:1039, 1994
34. Freedman AS, Nadler LM: Developments in purging in autotransplantation. Hematol Oncol Clin North Am 7:687, 1993
35. Gulati SC, Lemoli RM, Acaba L, Igarashi T, Wassarheit C, Fraig M: Purging in autologous and allogeneic bone marrow transplantation. Curr Opin Oncol 4:264, 1992
36. Geller RB: Role of autologous bone marrow transplantation for patients with acute and chronic leukemias. Hematol Oncol Clin North Am 7:547, 1993
37. Gee A: Purging of peripheral blood stem cell grafts. Stem Cells 13:52, 1995
38. Rizzoli V, Carlo-Stella C: Stem cell purging: An intriguing dilemma. Exp Hematol 23:296, 1995
39. Fitzgerald D: Why toxins! Semin Cancer Biol 7:87, 1996
40. Olsnes S, Sandvig K, Peterson OW, van Deurs B: Immunotoxins - Entry into cells and mechanisms of action. Immunol Today 10:291, 1989
41. Pudymaitis A, Lingwood CA: Susceptibility to verotoxin as a function of the cell cycle. J Cell Physiol 150:632, 1992
42. Ohyama C, Fukushi Y, Satoh M, Saitoh S, Orikasa S, Nudelman E, Straud M, Hakamori S-i: Changes in glycolipid expression in human testicular tumor. Int J Cancer 45:1040, 1990
43. Wenk J, Andrews PW, Casper J, Hata J-i, Pera MF, von Keitz A, Damjanov I, Fenderson BA: Glycolipids of germ cell tumors: Extended globo-series glycolipids are a hallmark of human embryonal carcinoma cells. Int J Cancer 58:108, 1994
44. Xhang X-g, Gaillard JP, Robillard N, Lu Z-Y, Gu Z-J, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:3654, 1994
45. Boyd B, Richardson S, Gariépy J: Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter the action of the toxin. Infect Immun 59:750, 1991